This is the authors' abstract. We don't add key points for this paper.
Small cell lung cancer (SCLC) is an aggressive high-grade neuroendocrine carcinoma. Despite over 30 years of clinical research, little progress has been made in the management of SCLC, and outcomes remain poor. Here, we review the current clinical standards for management of SCLC and the data supporting these strategies.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Farago et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: